Agios Pharmaceuticals Inc

NASDAQ:AGIO   3:59:50 PM EDT
48.37
+1.38 (+2.94%)
Products, Regulatory, Other Pre-Announcement

Agios Announces Updated Data From Phase 1 Study Of Mitapivat, First-In-Class Pkr Activator, In Sickle Cell Disease

Published: 12/07/2020 21:41 GMT
Agios Pharmaceuticals Inc (AGIO) - Agios Announces Updated Data From Phase 1 Study of Mitapivat, First-in-class Pkr Activator, in Sickle Cell Disease.
Agios Pharmaceuticals - Safety Profile Generally Consistent With Previously Presented Data in Patients With Pyruvate Kinase Deficiency and Thalassemia.
Agios Pharmaceuticals Inc - Data Support Advancement of Mitapivat to Pivotal Development in Sickle Cell Disease.
Agios Pharmaceuticals Inc - Company Expects to Initiate Pivotal Program in 2021.